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Abstract
Aims Undiagnosed atrial fibrillation (AF) accounts for 6% of all strokes, therefore early detection and treatment of the 
arrhythmia are paramount. Previous research has illustrated that the Microlife WatchBPO3 AFIB, an automated blood pres-
sure (BP) monitor with an inbuilt AF algorithm, accurately detects permanent AF. Currently, limited data exist on whether 
the modified BP monitor is able to detect paroxysmal AF (PAF). Therefore, this study aims to assess the accuracy of the 
Microlife WatchBPO3 AFIB monitor to detect PAF against a pacemaker reference standard over a 24-h period.
Methods and results Forty-eight patients with a pacemaker implanted for sick sinus syndrome and previously documented 
fast AF participated. Sensitivity of the atrial pacemaker lead was set to allow detection of signals of ≥ 0.5 mV. Patients 
engaged in their normal daily routine whilst wearing the modified BP monitor. The modified BP monitor demonstrated an 
overall sensitivity of 76.0% and specificity of 80.8% for detecting PAF. This sensitivity and specificity increased to 100% 
and 83.1%, respectively, for patients that achieved more than 80% successful BP readings. Compared to day-time readings, 
night-time readings also demonstrated a lower proportion of movement artefact (14.4% vs. 3.4%), and therefore, a higher 
sensitivity and specificity of 100% and 84.9%, respectively, for detecting PAF.
Conclusion The Microlife WatchBPO3 AFIB device has an acceptable diagnostic accuracy to detect PAF; however, move-
ment artefact affects the accuracy of the readings. This modified BP monitor may potentially be useful as a screening tool 
for AF in patients at high risk of developing stroke.
Keywords Atrial fibrillation · Blood pressure · Detection · Sensitivity · Specificity
Introduction
Atrial fibrillation (AF) is the most commonly encountered 
arrhythmia in clinical practice and is a powerful independ-
ent risk factor for stroke [1]. It is estimated that 15% of all 
strokes is attributable to AF, the majority of which are more 
severe, more likely to lead to disability, and more often 
fatal than other forms of strokes [2]. Since undiagnosed AF 
accounts for 3.8% to 6.1% of all strokes, detection of the 
arrhythmia is extremely crucial [3]. In spite of guidelines 
suggesting opportunistic manual pulse palpation in patients 
over 65 years old, symptomatic, or at high risk for stroke, 
paroxysmal AF (PAF) is frequently able to evade routine 
detection due to its intermittent, brief, and usually asymp-
tomatic episodes [4].
Previous research has shown that the Microlife Watch-
BPO3 AFIB, a modified automated blood pressure (BP) 
monitor, is able to accurately detect permanent AF with 
a sensitivity of 94.9–95% and specificity of 86–89.7% in 
outpatient clinics and primary care centres [5, 6]. With the 
exception of one study that demonstrated a sensitivity of 
100% and specificity of 93% to detect transient AF over 
30 days with multiple successive readings, there is cur-
rently a lack of research investigating the performance of 
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the Microlife WatchBPO3 AFIB over extended periods in 
at-home settings, and so it is generally unknown if this moni-
tor is able to detect PAF with the same level of accuracy [5].
Therefore, the purpose of this study was to examine the 
diagnostic accuracy of this modified BP monitor to detect 
PAF over a 24-h period among patients with a pacemaker 
implanted for sick sinus syndrome, who had previously 
documented fast AF and atrial high-rate episodes (AHRE). 
Glotzer et al. [7] confirmed that pacemakers have the ability 
to document brief episodes of AF using atrial high-rate epi-
sodes (AHRE) with an extremely high sensitivity of 100% 
and specificity of 97.6%. Given the high level of precision 
with which pacemakers can document brief episodes of AF, 
comparing the accuracy of the modified BP monitor against 
this, could provide valuable information for healthcare prac-
tice. If successful in identifying PAF, the Microlife Watch-
BPO3 AFIB may be useful as a screening tool in patients 
who are at high risk of developing stroke or are referred for 
ambulatory BP tests.
Methods
This observational study compared the diagnostic accuracy 
of the Microlife WatchBPO3 AFIB (Microlife, Heerbrugg, 
Switzerland) to detect PAF against the reference standard of 
an implanted pacemaker. The study protocol was approved 
by the West Midlands-Black Country Research Ethics 
Committee of the Health Research Authority (REC 13/
WM/0382, IRAS 114264), and the Sandwell and West Bir-
mingham Hospitals NHS Trust Research and Development 
Department (R&D 13CARD56). The study was registered 
with the National Institute of Health Clinical Trials Registry 
(Registration No. NCT02442505). All participants provided 
written informed consent.
Setting and participants
Patients were recruited from the cardiology outpatient 
clinic register at one NHS Trust in the West Midlands, 
UK. Patients with an implanted pacemaker for sick sinus 
syndrome and previously documented AF or AHRE were 
invited to participate in the study. Exclusion criteria included 
patients that (i) were unable to provide written informed 
consent, (ii) had previous pacemaker sensing issues on either 
the atrial or ventricular pacemaker lead, (iii) diagnosed with 
permanent AF, or (iv) had a VVI pacemaker.
Test procedure
Patients attended the cardiology outpatient department 
on two consecutive days. Subsequent to obtaining written 
informed consent, details on their demography, medical 
history, and pacemaker were recorded. Patients had their 
pacemaker interrogated, during which the sensitivity on the 
atrial lead was temporarily altered to allow for detection of 
signals of at least ≥ 0.5 mV and rates of at least ≥ 180 bpm. 
If the atrial lead possessed an autosensing feature, this was 
disabled. No other settings were changed. Patients were then 
fitted with the Microlife WatchBPO3 AFIB monitor. Based 
on their upper arm circumference, an appropriate cuff size 
was chosen and fitted 2–3 cm above the elbow. The cuff 
tube was placed around the upper arm, pointed upward, and 
mounted over the patient’s shoulder to allow the monitor to 
be placed in a pouch that hung around the neck. To mimic 
current clinical practice for 24-h ambulatory BP monitor-
ing and therefore allow for a better attempt at generalising 
results to the real-world setting, the modified BP monitor 
was automatically timed to take a reading every 30 min 
from 08:00 to 22:00 and every 60 min from 22:00 to 08:00 
[8]. Patients were asked to relax their arm, remain still, and 
refrain from talking during the BP measurement. Prior to 
leaving, the monitor was switched to ‘ambulatory’ mode. If 
patients were symptomatic over the 24 h, they were encour-
aged to record their symptoms on a diary sheet. Patients 
were then asked to engage in their usual daily routine for 
the next 24 h out of hospital. On the following day, patients 
returned to the department to have their modified BP moni-
tor removed and the data were downloaded from the device 
via computer software. Their pacemaker was interrogated 
to assess for AF or AHRE occurring in the last 24 h and 
thereafter re-programmed to the original settings. Pace-
maker-detected episodes of AF were analysed by a cardiac 
physiologist to confirm their accuracy.
Detection methods
Microlife WatchBPO3 AFIB is an oscillometric BP mon-
itor that possesses an additional independent feature to 
detect AF. The inbuilt algorithm analyses pulse irregular-
ity during the last 10 beats of cuff deflation by calculating 
the irregularity index, which is defined as the “standard 
deviation of the time intervals between successive heart-
beats divided by the mean of the intervals for the total 
number of beats analysed” [9]. To exclude incidental 
arrhythmias, each interval that deviates by 25% from the 
mean is discarded from the analysis. Diagnosis of AF is 
made if the irregularity index is above the threshold value 
of > 0.06 [9]. On the other hand, pacemaker detection of an 
atrial tachyarrhythmia is a continuous process. Most dual-
chamber pacemakers employ an automatic mode switch 
(AMS) algorithm to detect atrial tachyarrhythmias, which 
was designed to prevent its tracking through to the ventri-
cles and thereby maintain atrioventricular synchrony. By 
doing so, it also triggers an electrogram (EGM) storage of 
an AHRE [10]. AMS proves a reliable marker for detection 
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of atrial tachyarrhythmias with a reported sensitivity and 
specificity of 98.1% and 100%, respectively [11]. Further-
more, Microlife WatchBPO3 AFIB is also able to detect 
movement artefact, weak signals, and cuff leakage, provid-
ing a readout with a ‘remark’ for each individual reading.
Outcomes
The primary outcome of this study is to determine the sensi-
tivity, specificity, positive predictive value (PPV), and nega-
tive predictive value (NPV) of the modified BP monitor to 
detect PAF. One large clinical hypertension trial suggested 
that the percentage of valid BP readings obtained during 
24-h should exceed 80% of all readings attempted. There-
fore, the diagnostic accuracy (sensitivity, specificity, PPV, 
and NPV) of the modified BP monitor was also compared 
between patients that achieved above and below this thresh-
old [12]. Subgroup analyses of the diagnostic accuracy of 
the modified BP monitor during any movement artefact were 
also performed by assessing day- and night-time readings 
separately. Night-time was determined by each patients’ 
stated waking and sleeping hours on their diary sheet. For 
patients that did not provide this information, a set standard 
of 22:00–08:00 was used.
Statistical analyses
The Kolmogorov–Smirnov test was used to determine the 
normality of the distribution for continuous variables. Nor-
mally distributed variables are portrayed by mean ± standard 
deviation (SD), while non-normally distributed variables are 
reported as median and interquartile range (IQR). Sensitivity, 
specificity, PPV, and NPV were calculated as simple pro-
portions with corresponding 95% confidence intervals (95% 
CI). 95% CI were computed based on the binomial approxi-
mation. Pearson’s χ2 test was used to determine differences 
between categorical variables. For categorical variables with 
an expected count of less than 5, the likelihood ratio χ2 test 
was used instead. Pearson’s correlation test was used to deter-
mine univariate correlations between the percentage of AF 
readings detected by the modified BP monitor and the daily 
maximum burden of AF detected by the pacemaker. Statisti-
cal analysis was performed using IBM SPSS 24 (IBM Cor-
poration). Statistical significance was set at p < 0.05.
Results
Clinical characteristics
From 178 potential candidates for this study, 121 (68%) 
declined to participate. Fifty-seven patients met the inclusion 
criteria. Six withdrew, two were newly diagnosed with per-
manent AF, and one patient was deemed unsuitable as data 
between the implanted pacemaker and modified BP moni-
tor could not be accurately compared, resulting in a total 
of 48 (84%) patients being included in the final analysis. 
These patients ranged in age from 44 to 92 years with a 
mean (SD) age of 71.6 (10.9) years. The majority were male 
(58.3%), of white ethnicity (70.8%), had diagnosed hyper-
tension (66.7%), and were receiving anticoagulation therapy 
for paroxysmal AF (60.4%). Both clinical characteristics of 
and medications taken by included patients are summarised 
in Table 1.
Pacemaker function
Patients participating in the study had the following pace-
makers in  situ: Medtronic (75.1%), St. Jude Medical 
(20.6%), and Sorin (4.2%). Most pacemakers were dual-
chamber (97.9%) and implanted for symptomatic sinus arrest 
(39.6%). Further pacemaker details are provided in Table 1. 
Patients displayed normal pacemaker function over the 24 h 
testing period.
Detection of paroxysmal AF
From the 48 patients, 1595 modified BP monitor readings 
were collected for individual analysis. From these record-
ings, the prevalence of AF was 1.6% with a maximum AF 
burden of 5.4%, over the 24-h testing period. Overall, 4 out 
of 48 patients (8.3%) collectively exhibited 24 true PAF epi-
sodes. In these patients, 30-day AF burden ranged from 0.6 
to 77.6%, with those that had the highest number of AF epi-
sodes also having the highest AF burden. Figure 1 highlights 
the distribution of these episodes, showcasing those that 
were detected or undetected by the Microlife WatchBPO3 
AFIB monitor. Out of the 48 patients, only a single indi-
vidual (Patient B) reported one episode of light-headedness 
that corresponded to a true AF event. From the 1595 modi-
fied BP monitor readings, 19 were true positives, 9 were 
false negatives, 300 were false positives, and 1270 were true 
negatives (Table 2). Compared to the pacemaker, the Micro-
life WatchBPO3 AFIB monitor demonstrated a sensitivity 
of 76.0%, specificity of 80.8%, PPV of 5.9% and a NPV of 
99.5% to detect PAF. In the cohort that achieved more than 
80% successful BP readings, the sensitivity and specificity 
increased to 100% and 82.3%, respectively. Patients that did 
not achieve this threshold of successful BP readings demon-
strated a lower sensitivity of 76.0% and specificity of 76.9%. 
Due to only one true positive occurrence in this cohort, PPV 
was low at 0.5%, whilst NPV was high at 100%.
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Effect of movement artefact on diagnostic accuracy
Overall, there were more day-time readings than night-time 
readings (73.9% vs. 26.1%). Day-time readings demon-
strated more movement artefact than night-time readings 
but the difference was not significant (14.4% vs. 3.4%, like-
lihood ratio = 3.2, p = 0.08). Compared to night-time read-
ings, the modified BP monitor demonstrated lower sensi-
tivity, specificity, PPV, and NPV during day-time readings. 
Table 3 summarises the diagnostic accuracy of the Microlife 
WatchBPO3 AFIB monitor to detect PAF in each setting.
Correlation between AF burden on pacemaker 
and AF detected by modified BP monitor
A strong positive correlation was found between the per-
centage of AF burden (i.e. amount of time a patient spent 
in AF) recorded by the pacemaker over 30-days and the 
percentage of readings positive for AF detected by the 
modified BP monitor during the 24-h ambulatory period 
for all patients (r = 0.70, p < 0.001) (Supplemental Fig. 1). 
This correlation was further strengthened in patients that 
had more than 30% of readings positive for AF (r = 0.89, 
p = 0.001) highlighting that true-positive readings of AF 
Table 1  Clinical characteristics, medications, and pacemaker details 
of included patients
Variable Included 
patients 
(n = 48)
Current age (years) 71.6 ± 10.9
Age at pacemaker implant (years) 67.9 ± 11.0
Gender (n, %)
 Male 28 (58.3)
 Female 20 (41.7)
Height (cm) 167.9 ± 9.7
Weight (kg) 76.1 [21.0]
Body mass index (kg/m2) 27.0 [8.4]
Ethnicity (n, %)
 White 34 (70.8)
 Asian (Indian, Pakistani, Bangladeshi) 10 (20.8)
 Black/Caribbean 2 (4.2)
 Mixed 2 (4.2)
Congestive HF (n, %) 1 (2.1)
Hypertension (n, %) 32 (66.7)
Diabetes mellitus (n, %)
 Type I 0 (0)
 Type II 14 (29.2)
Previous stroke (n, %)
 Ischaemic 3 (6.3)
 Haemorrhagic 2 (4.2)
 Unspecified 3 (6.3)
Vascular disease (n, %)
 Prior myocardial infarction 5 (10.4)
 Coronary artery disease 12 (25.0)
 Peripheral artery disease 0 (0)
Hyperlipidaemia (n, %) 19 (39.6)
Other cardiovascular disease (n, %)
 Prior cardiac surgery 2 (4.2)
 Congenital 0 (0)
 Valvular 1 (2.1)
 Pericarditis 0 (0)
 Cardiomyopathy 0 (0)
Medications (n, %)
 Anticoagulants 29 (60.4)
 Antiplatelets 16 (33.3)
 ACE-inhibitors 15 (31.3)
 Angiotensin receptor blocker 8 (16.7)
 Beta-blockers 23 (47.9)
 Calcium-channel blockers 12 (25.0)
 Digitalis 2 (4.2)
 Diuretics 17 (35.4)
 Statins 31 (64.6)
 Vasodilators 8 (16.7)
Device model (n, %)
 Medtronic Adapta 8 (16.7)
 Medtronic Advisa 14 (29.2)
Mean ± standard deviation given for normally distributed variables, 
median [interquartile range] given for not normally distributed vari-
ables. Number (%) given for categorical variables
Table 1  (continued)
Variable Included 
patients 
(n = 48)
 Medtronic Ensura 6 (12.5)
 Medtronic Sensia 8 (16.7)
 St. Jude Accent 1 (2.1)
 St. Jude Assurity 7 (14.6)
 St. Jude Azure 2 (4.2)
 Sorin Reply 2 (4.2)
Mode (n, %)
 DDD 3 (6.3)
 DDDR 16 (33.3)
 DDI 1 (2.1)
 AAI-DDD 10 (20.8)
 AAIR-DDDR 17 (35.4)
 AAIR 1 (2.1)
Indication for implant (n, %)
 Sinus arrest 19 (39.6)
 Sinus bradycardia 18 (37.5)
 Brady-tachy syndrome 6 (12.5)
 Chronotropic incompetence 1 (2.1)
 Unspecified SSS 4 (8.3)
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are more likely to be detected by the modified BP monitor 
in patients with a higher overall burden of AF.
Discussion
This is the first study to investigate the diagnostic accuracy 
of the Microlife WatchBPO3 AFIB to detect PAF over a 
24-h ambulatory period. Our findings show that the Micro-
life WatchBPO3 AFIB device has an acceptable diagnostic 
accuracy to detect PAF; however, movement artefact affects 
the accuracy of the readings.
Compared to previous research that has established high 
diagnostic accuracy of modified BP monitors to detect per-
manent AF in outpatient clinics, the overall sensitivity and 
specificity reported in the current study was marginally 
lower [5, 6, 13]. Given that PAF is more difficult to detect 
in light of its brief and transient episodes, it is unsurprising 
that the sensitivity and specificity is higher in a permanent 
AF cohort. Ensuring the modified BP monitor has a high 
sensitivity is important for clinic visits, as screening oppor-
tunities are restricted to a limited number. This does not 
necessarily apply to ambulatory BP monitoring, which can 
collect up to 38 measurements a day, allowing for a higher 
chance of overall detection. Therefore, a lower sensitivity 
may be acceptable for frequent readings performed over an 
extended period of time.
Only one other study has attempted to detect PAF over 
30-days at home by performing a maximum of three succes-
sive readings on a daily basis [5]. Despite the high diagnos-
tic accuracy reported, self-performing sequential readings 
relies heavily on patient compliance for its efficacy. It may 
be a useful tool for detection of PAF in patients that already 
possess modified BP monitors at home, but issuing these 
for the general population to use over a prolonged period as 
Fig. 1  Distribution of true 
paroxysmal AF episodes with 
detection ability of Microlife 
WatchBPO3 AFIB
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Table 2  Modified BP monitor diagnoses of paroxysmal AF vs. pace-
maker diagnoses of paroxysmal AF
Positive AF pacemaker 
diagnosis
Negative AF 
pacemaker 
diagnosis
Positive AF modified 
BP monitor diagnosis
19 300
Negative AF modified 
BP monitor diagnosis
6 1270
Table 3  Sensitivity, specificity, PPV, and NPV with 95% CI of the Microlife WatchBPO3 AFIB to detect paroxysmal AF in various settings
a One-sided 97.5% confidence interval
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Overall (24-h) AF detection 76.0 (74–78) 80.8 (79–83) 5.9 (5–7) 99.5 (99–100)
Day-time AF detection 68.4 (66–71) 79.3 (77–81) 5.1 (4–6) 99.4 (99–100)
Night-time AF detection 100  (99a–100) 84.9 (83–87) 8.8 (7–10) 100 (99a–100)
AF detection in < 80% successful BP readings 76.0 (59–96) 76.9 (70–79) 15.4 (8–21) 98.3 (97–100)
AF detection in > 80% successful BP readings 100  (99a-100) 83.1 (80–86) 0.5 (0–4) 100 (99a–100)
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part of a screening process is time-consuming and unlikely 
to be cost-effective. Only one daily set of readings may fail 
to detect transient episodes, and therefore, 24-h ambulatory 
monitoring is a better alternative to increase the chances of 
detecting new AF cases.
Of note, the sensitivity and specificity in our cohort 
increased to 100% and 83.1% respectively, when only con-
sidering patients who achieved more than 80% of successful 
BP readings. It is important to note that even when a BP 
reading is not provided, the Microlife WatchBPO3 AFIB 
monitor has the ability to determine whether AF was occur-
ring at the time of inflation due to the independently func-
tioning algorithm for detection. Despite this, proposed stand-
ards suggest that a satisfactory recording should consist of 
at least 70–80% successful BP readings, and therefore, this 
criterion should be applied if using ambulatory modified BP 
monitors for the detection of PAF [14, 15]. One drawback of 
this modified BP monitor to detect PAF is the false positive 
rate of 19.2%, suggesting that approximately 1 in 5 readings 
was incorrectly identified as AF. Compared to patients who 
had a successful ambulatory recording, patients that did not 
display a higher false positive rate (34.2% vs. 16.9%), fur-
ther strengthening the argument that a successful ambulatory 
recording is required to improve the diagnostic accuracy for 
the detection of PAF. This study could not investigate the 
proportion of false positive readings potentially due to other 
arrhythmias. Despite the pacemaker’s continuous monitor-
ing for abnormal rhythms, it does not record an EGM for 
individual premature atrial or ventricular ectopics. Since 
patients with pacemakers are more likely to have cardiac 
arrhythmias, a large percentage of false-positive readings 
can be anticipated. Wiesel et al. [16] illustrated that 62% of 
ventricular ectopics and 43% of atrial ectopics were accu-
rately identified by the modified BP monitor as not being 
AF, resulting in a low specificity of 50% for patients with 
frequent ectopics. However, restricting this tool to patients 
without recurrent ectopics would result in at least half of 
this cohort not receiving its benefit. No formal indications 
exist on how false-positive readings may affect the diagnos-
tic accuracy if screening patients at high risk for stroke over 
a 24-h ambulatory period.
Furthermore, false-positive readings may arise as a result 
of excessive movement during measurements. Unlike in 
clinic visits, movement artefact is more likely to occur with 
prolonged ambulatory recording. Compared to night-time 
readings, our findings demonstrated that day-time readings 
had a higher proportion of movement artefact, which poten-
tially explains the lower overall diagnostic accuracy and con-
tribution to the increased false-positive rate by 7%. Because 
the modified BP monitor relies on the brachial pulse to 
determine irregularity, any excessive movement that would 
obstruct its analysis can cause erroneous results. Ensuring 
patients optimise their positioning during the measurements 
should be emphasized in all ambulatory BP recordings. 
Future research should compare the modified BP monitor 
to a 24-h ECG, which would provide more insight on the 
proportion of false-positive readings discernable to either 
movement or other arrhythmias.
Given the high false-positive rate, criteria are required 
to determine which patients receive additional ECG moni-
toring to officially diagnose PAF. Based on the correlation 
between false-positive readings and ectopics, Kollias et al. 
[17] concluded that patients over 50 years old with > 30% of 
positive readings are highly likely to have true AF. One trial 
revealed more than 5.5 h of AHRE was shown to signifi-
cantly increase the risk of stroke [18]. If a patient had > 30% 
of all true-positive readings for AF, it would suggest that 
PAF was present for at least 7 of the 24 h. By prioritis-
ing further testing to patients with > 30% of positive read-
ings, the economic burden created by false-positive read-
ings could be reduced. The current study provides further 
insights, highlighting a strong positive correlation between 
the overall time spent in AF over 30-days as detected by 
the pacemaker and the proportion of true-positive readings 
for AF over the 24-h ambulatory period as detected by the 
modified BP monitor. Patients with > 30% positive readings 
for AF had a significantly higher overall burden of AF over 
30-days, suggesting that prioritising follow-on diagnostic 
testing to this group ensures that patients with a significant 
amount of PAF can be identified and administered appropri-
ate treatment to decrease the risk of stroke. By employing 
this criteria in clinical practice, the Microlife WatchBPO3 
AFIB monitor could function as an accurate triage tool in 
patients with hypertension, in those at high risk of develop-
ing AF (≥ 65 years with > 1 stroke risk factor), and in those 
at high risk of stroke.
It is important to note that PAF can never truly be ruled-out. 
Due to its nature, brief episodes are common and can occur in 
between the automatically timed BP readings or outside of the 
24-h monitoring period altogether. Therefore, clinicians should 
not rely solely on the modified BP monitor to draw any final 
conclusions. Instead of employing it as a ‘rule-out’ test, the 
Microlife WatchBPO3 AFIB monitor is more appropriate in 
an opportunistic screening setting. Two studies have demon-
strated a detection rate for newly diagnosed AF of up to 6.9% 
on a single reading [19, 20]. Since hypertension is the most 
independent risk factor for AF, the ability to simultaneously 
and accurately screen for PAF in patients who are referred for 
ambulatory BP monitoring is valuable. Given that the risk can 
be reduced with early and appropriate anticoagulant treatment, 
the identification of PAF is paramount [21, 22]. Even though a 
24-h ECG may be the gold-standard detection tool, the analy-
sis is cumbersome and time-consuming. Therefore, modified 
BP monitors are a more convenient and quicker alternative.
Considering that the sensitivity of the modified BP moni-
tor to detect paroxysmal AF in the current study is 76.0%, 
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there is a probability that 3 out of 10 patients with PAF could 
be overlooked by this screening tool. Our study reported 
an extremely low false-negative rate of 0.4%. On further 
investigation, the false-negative readings all stemmed from 
two patients that had a poor ambulatory BP recording of 
less than 65% successful readings, further emphasising that 
patients should achieve at least 80% valid BP readings for 
accurate detection of PAF. One plausible reason for false 
negative readings is how the pacemaker is arranged to pro-
tect the patient from atrial tachyarrhythmias, resulting in the 
modified BP monitor detecting the paced pulses delivered 
by the pacemaker, deeming the rhythm as regular, when in 
reality the patient is undergoing PAF. It is also possible that 
weak pulse signals as a result of an arrhythmia may go unde-
tected by the modified BP monitor.
Limitations
Due to the limited sample size, this study is not powered 
to produce statistically significant effects. Nevertheless, the 
simultaneous recording of the modified BP monitor and 
implanted pacemaker allows for accurate comparison. Other 
studies did not ensure that recordings were performed simul-
taneously [5, 16, 19, 20]. Compared to ambulatory ECG 
monitors, previous research has shown that pacemakers have 
a sensitivity of 98% and specificity of 100% to detect atrial 
tachyarrhythmias [23]. Despite this, employing a 24-h ECG 
monitor would have provided valuable information on any 
under-detection of arrhythmias (including those other than 
AF), short AHREs, or automatic mode switch events that 
may have caused either false negative or positive readings. 
Even though larger numbers of participants were enrolled 
in other studies, only a range of 1–3 readings was taken per 
individual. Contrarily, this study collected a total of 1595 
readings over a 24-h period.
Conclusion
In conclusion, the Microlife WatchBPO3 AFIB device has 
an acceptable diagnostic accuracy to detect PAF; however, 
movement artefact affects the accuracy of the readings. This 
modified BP monitor may potentially be useful as a screen-
ing tool for AF in patients at high risk of developing stroke.
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